Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY
Leerink Partners Initiates Coverage On Latigo Biotherapeutics with Outperform Rating, Announces Price Target of $36
Jefferies Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50
Guggenheim Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50
Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued
Reported Earlier, Latigo Biotherapeutics Files To Sell Up To 16M IPO Shares Priced At $16-$18 Per Share
Latigo Biotherapeutics Commences IPO Process For Pain Treatment Pipeline
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
